Hypebeast(00150.HK)向Avex Entertainment溢價15%配股籌692萬元
Hypebeast(00150.HK)公布,與Avex Entertainment Inc訂立投資協議,將向其配發及發行近653.34萬股股份,佔擴大後發行股份約0.32%。認購價為每股1.05924元,較今日(25日)收市價0.92元溢價約15.13%,總代價為692.04萬元,於投資協議日期相當於約1億日圓。
公司預期,引入Avex Entertainment將促進雙方的戰略業務計劃合作,可利用投資者在日本的深厚國內網絡及本地專業知識,以及其在活動製作、藝人管理及音樂唱片行業的領先地位,令集團日本業務加快增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.